Wall Street analysts forecast that Viatris (VTRS) will report quarterly earnings of $0.57 per share in its upcoming release, pointing to a year-over-year decline of 6.6%. It is anticipated that revenues will amount to $3.6 billion, exhibiting a decline of 6.3% compared to the year-ago quarter.

The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

In light of this perspective, let's dive into the average estimates of certain Viatris metrics that are commonly tracked and forecasted by Wall Street analysts.

The average prediction of analysts places 'Total Net Sales' at $3.59 billion. The estimate suggests a change of -6.2% year over year.

Analysts predict that the 'Other revenues' will reach $11.47 million. The estimate suggests a change of +0.6% year over year.

Analysts forecast 'Net Sales- JANZ' to reach $366.35 million. The estimate indicates a change of -1.6% from the prior-year quarter.

The combined assessment of analysts suggests that 'Net Sales- Emerging Markets' will likely reach $538.93 million. The estimate points to a change of -13% from the year-ago quarter.

The collective assessment of analysts points to an estimated 'Net Sales- Developed Markets- Brands' of $1.21 billion. The estimate suggests a change of -7.7% year over year.

The consensus estimate for 'Net Sales- JANZ- Brands' stands at $198.33 million. The estimate indicates a change of -0.6% from the prior-year quarter.

Analysts' assessment points toward 'Net Sales- JANZ- Generics' reaching $168.03 million. The estimate indicates a year-over-year change of -13.1%.

It is projected by analysts that the 'Net Sales- Emerging Markets- Brands' will reach $401.94 million. The estimate indicates a change of +7.3% from the prior-year quarter.

According to the collective judgment of analysts, 'Net Sales- Emerging Markets- Generics' should come in at $171.99 million. The estimate indicates a year-over-year change of -29.7%.

The consensus among analysts is that 'Net Sales- Greater China' will reach $553.04 million. The estimate indicates a year-over-year change of +7.3%.

Based on the collective assessment of analysts, 'Net Sales- Developed Markets' should arrive at $2.17 billion. The estimate suggests a change of -6.5% year over year.

Analysts expect 'Net Sales- Developed Markets- Generics' to come in at $1.06 billion. The estimate indicates a change of -26.1% from the prior-year quarter.

View all Key Company Metrics for Viatris here>>>

Shares of Viatris have experienced a change of +0.5% in the past month compared to the -0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), VTRS is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Viatris Inc. (VTRS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research